Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

被引：35
作者：
Tilly, H. [1 ]
Morschhauser, F. [2 ]
Salles, G. [3 ]
Casasnovas, R-O [4 ]
Feugier, P. [5 ]
Molina, T. J. [6 ]
Jardin, F. [1 ]
Terriou, L. [2 ]
Haioun, C. [7 ]
Coiffier, B. [3 ]
机构：
[1] Univ Rouen, Ctr Henri Becquerel, UMR918, Dept Hematol, Rouen, France
[2] CHU Lille, F-59037 Lille, France
[3] Univ Lyon 1, Hosp Civils Lyon, F-69365 Lyon, France
[4] CHU Dijon, Dijon, France
[5] CHU Nancy, Nancy, France
[6] Univ Paris 05, Hotel Dieu, AP HP, Paris, France
[7] Hop Henri Mondor, F-94010 Creteil, France
来源：
LEUKEMIA | 2013年 / 27卷 / 01期
关键词：
FOLLICULAR LYMPHOMA; CHEMOTHERAPY;
D O I：
10.1038/leu.2012.172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：252 / 255
页数：5
相关论文
共 12 条
  • [1] Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival-A Study From the Groupe d'Etude des Lymphomes de l'Adulte
    Bachy, Emmanuel
    Brice, Pauline
    Delarue, Richard
    Brousse, Nicole
    Haioun, Corinne
    Le Gouill, Steven
    Delmer, Alain
    Bordessoule, Dominique
    Tilly, Herve
    Corront, Bernadette
    Allard, Christian
    Foussard, Charles
    Bosly, Andre
    Coiffier, Bertrand
    Gisselbrecht, Christian
    Solal-Celigny, Philippe
    Salles, Gilles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) : 822 - 829
  • [2] Lenalidomide for the treatment of B-cell malignancies
    Chanan-Khan, Asher A.
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1544 - 1552
  • [3] Fowler N, 2011, ANN ONCOL, V22, P128
  • [4] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    Hiddemann, W
    Kneba, M
    Dreyling, M
    Schmitz, N
    Lengfelder, E
    Schmits, R
    Reiser, M
    Metzner, B
    Harder, H
    Hegewisch-Becker, S
    Fischer, T
    Kropff, M
    Reis, HE
    Freund, M
    Wörmann, B
    Fuchs, R
    Planker, M
    Schimke, J
    Eimermacher, H
    Trümper, L
    Aldaoud, A
    Parwaresch, R
    Unterhalt, M
    [J]. BLOOD, 2005, 106 (12) : 3725 - 3732
  • [5] Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
    Nowakowski, G. S.
    LaPlant, B.
    Habermann, T. M.
    Rivera, C. E.
    Macon, W. R.
    Inwards, D. J.
    Micallef, I. N.
    Johnston, P. B.
    Porrata, L. F.
    Ansell, S. M.
    Klebig, R. R.
    Reeder, C. B.
    Witzig, T. E.
    [J]. LEUKEMIA, 2011, 25 (12) : 1877 - 1881
  • [6] Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
    Pettengell, Ruth
    Johnson, Hans E.
    Lugtenburg, Pieternella J.
    Salar Silvestre, Antonio
    Duehrsen, Ulrich
    Rossi, Francesca G.
    Schwenkglenks, Matthias
    Bendall, Kate
    Szabo, Zsolt
    Jaeger, Ulrich
    [J]. SUPPORTIVE CARE IN CANCER, 2012, 20 (03) : 647 - 652
  • [7] Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
    Ramsay, Alan G.
    Clear, Andrew J.
    Kelly, Gavin
    Fatah, Rewas
    Matthews, Janet
    MacDougall, Finlay
    Lister, T. Andrew
    Lee, Abigail M.
    Calaminici, Maria
    Gribben, John G.
    [J]. BLOOD, 2009, 114 (21) : 4713 - 4720
  • [8] Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
    Salles, Gilles
    Seymour, John Francis
    Offner, Fritz
    Lopez-Guillermo, Armando
    Belada, David
    Xerri, Luc
    Feugier, Pierre
    Bouabdallah, Reda
    Catalano, John Vincent
    Brice, Pauline
    Caballero, Dolores
    Haioun, Corinne
    Pedersen, Lars Moller
    Delmer, Alain
    Simpson, David
    Leppa, Sirpa
    Soubeyran, Pierre
    Hagenbeek, Anton
    Casasnovas, Olivier
    Intragumtornchai, Tanin
    Ferme, Christophe
    da Silva, Maria Gomes
    Sebban, Catherine
    Lister, Andrew
    Estell, Jane A.
    Milone, Gustavo
    Sonet, Anne
    Mendila, Myriam
    Coiffier, Bertrand
    Tilly, Herve
    [J]. LANCET, 2011, 377 (9759) : 42 - 51
  • [9] Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
    Witzig, Thomas E.
    Wiernik, Peter H.
    Moore, Timothy
    Reeder, Craig
    Cole, Craig
    Justice, Glen
    Kaplan, Henry
    Voralia, Michael
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Vose, Julie M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5404 - 5409
  • [10] Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu, Lei
    Adams, Mary
    Carter, Troy
    Chen, Roger
    Muller, George
    Stirling, David
    Schafer, Peter
    Bartlett, J. Blake
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4650 - 4657
12